PD 168368 | CAS#204066-82-0|NMB Receptor Antagonist

PD 168368
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 532455

CAS#: 204066-82-0

Description: PD 168368 is a competitive antagonist of neuromedin B (NMB) receptors (Kis = 15-45 nM for rat and human receptors expressed in various cell lines). It blocks the elevation of intracellular calcium and release of inositol phosphate induced by NMB in cells expressing NMB receptors.

Chemical Structure

PD 168368

CAS# 204066-82-0

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 532455
Name: PD 168368
CAS#: 204066-82-0
Chemical Formula: C31H34N6O4
Exact Mass: 554.26
Molecular Weight: 554.651
Elemental Analysis: C, 67.13; H, 6.18; N, 15.15; O, 11.54

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 350
10mg	USD 540
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: PD 168368; PD168368; PD-168368.

IUPAC/Chemical Name: (2S)-3-(1H-indol-3-yl)-2-methyl-2-[(4-nitrophenyl)carbamoylamino]-N-[(1-pyridin-2-ylcyclohexyl)methyl]propanamide

InChi Key: AFDXUTWMFMAQJO-PMERELPUSA-N

InChi Code: InChI=1S/C31H34N6O4/c1-30(19-22-20-33-26-10-4-3-9-25(22)26,36-29(39)35-23-12-14-24(15-13-23)37(40)41)28(38)34-21-31(16-6-2-7-17-31)27-11-5-8-18-32-27/h3-5,8-15,18,20,33H,2,6-7,16-17,19,21H2,1H3,(H,34,38)(H2,35,36,39)/t30-/m0/s1

SMILES Code: O=C(NCC1(C2=NC=CC=C2)CCCCC1)[C@](NC(NC3=CC=C([N+]([O-])=O)C=C3)=O)(C)CC4=CNC5=C4C=CC=C5

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	PD 168368 is a potent, competitive, and selective neuromedin B receptor (NMB-R) antagonist with the Ki of 15–45 nM.
In vitro activity:	The present study found that NMB and its receptor NMBR are aberrantly expressed in cervical cancer. NMB activates ERK1/2 and NF-κB signaling pathways, which promote the proliferation of cervical cancer cells and increase the expression of tumor necrosis factor α (TNF-α). The downregulation of NMBR by the specific inhibitor, PD168368, abrogates proliferation and promotes apoptosis of cervical cancer cells. Reference: Pathol Res Pract. 2022 Sep 6;238:154104. https://pubmed.ncbi.nlm.nih.gov/36095918/
In vivo activity:	As shown in Fig. 4D, the aortas of CKD rats had extensive calcification as compared with those from the sham rats. This was significantly alleviated in the aortas of the animals from PD168368-treated CKD group, resulting in reduced deposition of calcium as well as a small ratio of calcified area. The serum level of NMB was also increased in CKD rats compared with sham rats, which was restored to normal levels by PD 168368 treatment (Fig. 4E). Finally, western blotting demonstrated that PD168368 treatment blocked the osteogenic conversion and apoptosis in the aorta of CKD rats (Fig. 4F). Reference: BMB Rep. 2021 Nov;54(11):569-574. https://pubmed.ncbi.nlm.nih.gov/34674793/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMF	10.0	18.03
	DMSO	30.0	54.09
	DMSO:PBS (pH 7.2) (1:2)	0.3	0.54

Preparing Stock Solutions

The following data is based on the product molecular weight 554.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Zeng R, Xiong X. Effect of NMB-regulated ERK1/2 and p65 signaling pathway on proliferation and apoptosis of cervical cancer. Pathol Res Pract. 2022 Sep 6;238:154104. doi: 10.1016/j.prp.2022.154104. Epub ahead of print. PMID: 36095918. 2. Park HJ, Kim MK, Choi KS, Jeong JW, Bae SK, Kim HJ, Bae MK. Neuromedin B receptor antagonism inhibits migration, invasion, and epithelial-mesenchymal transition of breast cancer cells. Int J Oncol. 2016 Sep;49(3):934-42. doi: 10.3892/ijo.2016.3590. Epub 2016 Jun 30. PMID: 27571778. 3. Park HJ, Kim MK, Kim Y, Kim HJ, Bae SK, Bae MK. Neuromedin B modulates phosphate-induced vascular calcification. BMB Rep. 2021 Nov;54(11):569-574. doi: 10.5483/BMBRep.2021.54.11.089. PMID: 34674793; PMCID: PMC8633520. 4. Moody TW, Jensen RT, Garcia L, Leyton J. Nonpeptide neuromedin B receptor antagonists inhibit the proliferation of C6 cells. Eur J Pharmacol. 2000 Dec 8;409(2):133-42. doi: 10.1016/s0014-2999(00)00828-1. PMID: 11104826.
In vitro protocol:	1. Zeng R, Xiong X. Effect of NMB-regulated ERK1/2 and p65 signaling pathway on proliferation and apoptosis of cervical cancer. Pathol Res Pract. 2022 Sep 6;238:154104. doi: 10.1016/j.prp.2022.154104. Epub ahead of print. PMID: 36095918. 2. Park HJ, Kim MK, Choi KS, Jeong JW, Bae SK, Kim HJ, Bae MK. Neuromedin B receptor antagonism inhibits migration, invasion, and epithelial-mesenchymal transition of breast cancer cells. Int J Oncol. 2016 Sep;49(3):934-42. doi: 10.3892/ijo.2016.3590. Epub 2016 Jun 30. PMID: 27571778.
In vivo protocol:	1. Park HJ, Kim MK, Kim Y, Kim HJ, Bae SK, Bae MK. Neuromedin B modulates phosphate-induced vascular calcification. BMB Rep. 2021 Nov;54(11):569-574. doi: 10.5483/BMBRep.2021.54.11.089. PMID: 34674793; PMCID: PMC8633520. 2. Moody TW, Jensen RT, Garcia L, Leyton J. Nonpeptide neuromedin B receptor antagonists inhibit the proliferation of C6 cells. Eur J Pharmacol. 2000 Dec 8;409(2):133-42. doi: 10.1016/s0014-2999(00)00828-1. PMID: 11104826.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Ryan RR, Katsuno T, Mantey SA, Pradhan TK, Weber HC, Coy DH, Battey JF, Jensen RT. Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368. J Pharmacol Exp Ther. 1999 Sep;290(3):1202-11. PubMed PMID: 10454496.

Your view history

PD 168368 featured